May 2026 | Neuroscience News Roundup

May 14, 2026

This month's pediatric neuroscience developments highlight major advances in early autism detection, pediatric attention research, neurodevelopmental genetics, infant brain maturation, and systems-based pediatric neurology care. These findings reinforce the growing role of precision medicine and early intervention in child neurology.



Early Autism Detection Through Wearable Technology

Researchers at UCLA Health are developing wearable sensor technology capable of detecting subtle motor abnormalities in infants at high risk for autism spectrum disorder (ASD). The study uses wrist- and ankle-based sensors combined with machine learning algorithms to identify movement variability before traditional behavioral symptoms emerge.


Why This Matters

Motor differences often precede language and social communication changes in ASD. Earlier identification could allow intervention during critical neurodevelopmental windows when neuroplasticity is greatest.


Clinical Implications for Pediatric Neuroscience Nurses

  • Increased emphasis on developmental surveillance during infancy
  • Potential integration of digital biomarkers into pediatric neurology clinics
  • Expanded family education regarding early motor signs of ASD


References

  • Nature Reviews Neurology
    Lord, C., et al. (2020).     Autism spectrum disorder. Nature Reviews Disease Primers, 6, 5.
  • JAMA Pediatrics
    Landa, R. J., et al. (2013).     Developmental trajectories in infants with autism spectrum disorders. JAMA Pediatrics, 167(7), 629–638. 



Brain Signals May Predict Attention Lapses in Children

A newly identified neural “attention signature” may predict lapses in attention before they occur in children. Investigators demonstrated that real-time recognition of this brain signal could restore focus using targeted interventions.


Why This Matters

This research may have implications for:

  • ADHD diagnostics
  • Pediatric cognitive rehabilitation
  • Neurofeedback interventions
  • Classroom attention monitoring technologies


Clinical Implications

  • Future development of individualized neurocognitive therapies
  • Potential non-pharmacologic interventions for attention disorders
  • Improved objective biomarkers for pediatric attentional dysfunction


References

  • Neuron
    Posner, M. I., & Petersen, S. E. (1990).     The attention system of the human brain. Neuron, 13(1), 25–42.
  • Biological Psychiatry
    Castellanos, F. X., & Proal, E. (2012).     Large-scale brain systems in ADHD. Biological Psychiatry, 72(3), 192–197. 



Infant Sleep Emerging as a Neurodevelopmental Biomarker

A new review in Pediatric Research emphasizes the critical relationship between infant sleep architecture and early brain development. Researchers highlight sleep spindle maturation as a potential biomarker for neurodevelopmental outcomes.


Why This Matters

Sleep quality and organization during infancy may influence:

  • Cognitive development
  • Memory consolidation
  • Synaptic maturation
  • Long-term neurodevelopmental outcomes


Clinical Implications

  • Reinforces importance of sleep assessment in developmental evaluations
  • Supports parent education on sleep hygiene
  • May influence NICU and infant follow-up practices


References

  • Sleep Medicine Reviews
    Jan, J. E., et al. (2010).     Sleep hygiene for children with neurodevelopmental disabilities. Sleep Medicine Reviews, 14(6), 389–396.
  • Nature Reviews Neuroscience
    Frank, M. G. (2011).     Sleep and synaptic plasticity in the developing brain. Nature Reviews Neuroscience, 12, 477–488. 



New Genetic Insights Into Neurodevelopmental Disorders

Researchers from Baylor College of Medicine and Texas Children’s Hospital identified a gene-disease association involving ASTN1, a gene critical for neuronal migration and cortical development.


Why This Matters

The findings help explain previously undiagnosed neurodevelopmental syndromes and reinforce the role of genetic sequencing in pediatric neurology.


Clinical Implications

  • Expanding role of neurogenetics in diagnostic evaluation
  • Increased importance of interdisciplinary genetic counseling
  • Potential future precision therapies targeting neuronal migration pathways


References

  • Lancet Neurology
    Guerrini, R., & Dobyns, W. B. (2014).     Malformations of cortical development. Lancet Neurology, 13(7), 710–726.
  • Neuron
    Valiente, M., & Marín, O. (2010).     Neuronal migration mechanisms. Neuron, 66(4), 573–587. 



Early Screen Exposure & Adolescent Brain Outcomes

Longitudinal data continue to show associations between excessive screen exposure before age two and later anxiety symptoms, altered cognitive flexibility, and changes in brain network maturation.


Why This Matters

This reinforces concerns surrounding early digital exposure during sensitive neurodevelopmental periods.


Clinical Implications

  • Strengthens anticipatory guidance recommendations for families
  • Encourages developmental counseling around media exposure
  • Supports integration of environmental history into pediatric assessments

 

References

  • Pediatrics
    Madigan, S., et al. (2019).     Association between screen time and children’s performance on developmental screening tests. Pediatrics, 143(4).
  • JAMA Pediatrics
    Hutton, J. S., et al. (2020).     Associations between screen-based media use and brain white matter integrity. JAMA Pediatrics, 174(1), e193869. 



Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the first quarter ended March 31, 2026, and announced new 4-year longitudinal data from the ongoing Phase 1/2a open-label extension (OLE) studies that provide additional support for zorevunersen as a potential disease-modifying treatment for Dravet syndrome. Statistically significant improvements were demonstrated in cognition and behavior at 1, 2, 3 and 4 years of treatment compared to OLE baseline. Reductions in major motor seizure frequency were observed through 4 years of treatment in patients taking standard anti-seizure medicines (ASMs). Zorevunersen continues to be generally well tolerated, with some patients treated for more than 5 years in the Phase 1/2a and ongoing OLE studies.


The Company also announced an update on progress of the global Phase 3 EMPEROR study. Enrollment of approximately 150 patients in the U.S., UK and Japan is expected to complete in June 2026 to support a data readout in mid-2027. These data are anticipated to complete the rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) planned to initiate in the first quarter of 2027.


Read the full press release here: https://investor.stoketherapeutics.com/news-releases/news-release-details/stoke-therapeutics-announces-first-quarter-2026-financial

August 31, 2026 | Latest News & Updates in Child Neurology Nursing

August 31, 2026
Precision epilepsy treatment moves toward individualized ASOs One of the most clinically exciting recent papers is a Nature Medicine study describing individualized antisense oligonucleotides (ASOs) for children with SCN2A-related developmental epileptic encephalopathy. The investigators developed mutation-specific ASOs designed to correct the molecular consequences of individual SCN2A variants. Importantly, the work moves beyond the concept of precision medicine toward patient-specific molecular therapy, with implications for other genetic epilepsies. Why it matters for pediatric neuroscience nursing Genetic diagnosis may increasingly identify a treatable molecular mechanism, rather than simply provide an explanation. Nurses and APPs will increasingly be involved in education around individualized genetic therapies and longitudinal monitoring. Key Reference Kim-McManus, O., Mignon, L., Douville, J., et al. (2026). Individualized antisense oligonucleotides for SCN2A-related developmental epileptic encephalopathy. Nature Medicine, 32 , 2838–2845. https://doi.org/10.1038/s41591-026-04527-y. . What happens when the father takes valproate? A large study published this month in Neurology examined whether paternal valproate exposure around conception is associated with neurodevelopmental disorders or congenital malformations in offspring. Researchers analyzed more than 2.5 million children in Taiwan, including 1,701 whose fathers had been prescribed valproate during the three months before conception. After adjustment for multiple confounders—and in a sibling comparison—the investigators found no significant association between paternal valproate exposure and autism, ADHD, intellectual disability, tic disorders, or congenital malformations. This is particularly interesting because the reproductive safety concerns surrounding valproate have historically focused heavily on maternal exposure. Important caveat: This study does not change the well-established concerns regarding valproate exposure during pregnancy. The authors also emphasize limitations, including variable follow-up duration and the need for additional studies in other populations. Key Reference Feng, Y.-C. A., et al. (2026). Paternal valproate exposure and offspring neurodevelopmental outcomes. Neurology . Published August 19, 2026. DOI: 10.1212/WNL.0000000000218375. The brain environment can drive pediatric brain tumor biology A recent Nature Neuroscience paper provides another important advance in understanding pediatric brain tumors. Researchers identified a signaling pathway involving neuroligin-3 (NLGN3), CSPG4 and PIEZO1 that links neuronal activity with oligodendrocyte precursor cell biology and glioma proliferation. The study demonstrates that neuronal activity isn't simply something occurring around a tumor—the neural environment can actively influence tumor-cell behavior. The finding is particularly relevant to pediatric neuro-oncology because high-grade gliomas and diffuse midline gliomas remain among the most challenging childhood brain tumors. The authors describe how gliomas can exploit mechanisms normally involved in glial plasticity and myelination. This represents a broader shift in neuro-oncology: The tumor is not an isolated mass—it is part of a dynamic neural ecosystem. That concept could eventually lead to treatments targeting neuron–tumor interactions, rather than tumor cells alone. Key Reference Kim, Y. S., Gillespie, S. M., Geraghty, A. C., et al. (2026). Neuroligin-3–CSPG4 interaction maintains oligodendrocyte precursor cell progenitor state and promotes glioma proliferation through mechanotransduction. Nature Neuroscience . Published August 6, 2026. https://doi.org/10.1038/s41593-026-02397-8. 

August 18, 2026 | Latest News & Updates in Child Neurology Nursing

August 18, 2026
Early EEG changes may predict response to ketogenic diet in pediatric drug-resistant epilepsy A new study examined EEG changes shortly after children with drug-resistant epilepsy started a ketogenic diet. The investigators found that early electroencephalographic changes were associated with subsequent clinical response. This is particularly relevant to epilepsy nurses who educate families starting ketogenic therapy. It highlights the potential value of early EEG biomarkers alongside clinical seizure monitoring , and reinforces the importance of coordinated follow-up between families, nursing teams, dietitians, epileptologists, and EEG services. ACNN Takeaway Could early EEG changes help us identify which children are most likely to benefit from ketogenic therapy? Key Reference Early Electroencephalographic Changes After Ketogenic Diet Therapy in Pediatric Drug-Resistant Epilepsy. Seizure: European Journal of Epilepsy. 2026. Point-of-care EEG is gaining attention in pediatric emergency care A study recently published evaluated clinical selection of point-of-care EEG (POC-EEG) for children presenting to a pediatric emergency department with seizures or altered mental status. This is an especially relevant development for neuroscience nurses because rapid EEG availability could potentially shorten the time to recognition of nonconvulsive seizures and status epilepticus . ACNN Takeaway As POC-EEG becomes more accessible, neuroscience nurses may increasingly be involved in identifying appropriate patients, initiating monitoring, troubleshooting equipment, and recognizing when escalation is needed. Key Reference Toro-Perez J, et al. Components of generalized onset seizures with focal evolution progressing to bilateral tonic-clonic seizures using quantitative electroencephalography in children: Focal or generalized? Epilepsia. 2026. Pediatric epilepsy workforce development is getting attention A new article in Pediatric Neurology examines training pathways, workforce distribution, and professional development in pediatric neurology. This is particularly relevant to ACNN given the ongoing need to develop and retain a highly skilled pediatric neuroscience workforce. There is an important opportunity here to broaden the conversation beyond physician workforce numbers to include nursing, APPs, epilepsy specialists, EEG technologists, educators, and other members of the multidisciplinary team. Key Reference Training pathways, workforce distribution, and professional practice of child neurologists in Brazil: A cross-sectional study with implications for access. Pediatric Neurology. Published online August 6, 2026. Emerging technology stories worth watching Two new preprints are exploring AI approaches to epilepsy: EpiLENS uses patient-specific intracranial EEG patterns to improve localization of the epileptogenic zone across different patients and centers. Another new study explores deep-learning analysis of EEG biomarkers in Fragile X syndrome , focusing on alpha and gamma activity.

June 30, 2026 | Latest News & Updates in Child Neurology Nursing

July 9, 2026
Early risk stratification: HINE global scores predict neurodevelopmental outcomes A new systematic review and meta-analysis pooling 21 studies and 7,299 infants offers pediatric teams sharper, earlier tools for flagging infants at risk of adverse neurodevelopmental outcomes. Researchers examined Hammersmith Infant Neurological Examination (HINE) global scores collected at 3 months (corrected age), 6, 9, and 12 months, and mapped specific cutoffs to outcomes measured after age 2. The headline finding: a HINE global score below 58 at 3 months predicted cerebral palsy with a sensitivity of 79.6% and specificity of 88.7%. The analysis also identified threshold scores signaling atypical motor development, impaired cognitive, and broader atypical neurodevelopment. The authors conclude that HINE global scores at defined cutoffs provide early, robust risk stratifications supporting timely referral to pediatric rehabilitation during the window when early intervention matters most. Key Reference Kuo T-J, Chen H-C, Wang Y-H, Tseng S-H. Hammersmith Infant Neurological Examination global scores for predicting neurodevelopmental outcomes after 2 years of age: A systematic review and meta-analysis. First published 30 June 2026. Medication safety: caution with sodium channel blockers in HCN1-related epilepsy A new case series reported worsening of seizures in children with gain-of-function HCN1-related epilepsy treated with antiseizure medications that block sodium channels, leading the authors to advise that sodium-channel-blocking drugs be used with caution in this population. The practical takeaway for bedside teams is the value of confirming the genetic diagnosis before finalizing an antiseizure regimen, since the appropriate mechanism of action can differ by underlying variant—and a medication that helps one epilepsy type can aggravate another. Key Reference Lelli S, Bleakley LE, Ackermann S, Howell KB, Szczałuba K, Moroni A, Castelli R, Melani F, Reid C, Marini C. Seizure worsening and sodium channel blockers in HCN1-related epilepsies: A case series. *Developmental Medicine & Child Neurology.* First published 25 June 2026. Family-centered care: sleep disturbances in children with cerebral palsy affect the whole family A qualitative descriptive study interviewed children with cerebral palsy who had clinically significant sleep disturbances, along with their parents and siblings, to understand how disrupted sleep affects the whole family unit—not just the patient. Six themes emerged from the interviews, and together they point to a clear need for tailored, multidisciplinary, holistic sleep assessment and intervention, plus dedicated support for the family. The takeaway for care teams is that pediatric sleep problems ripple outward to parents and siblings, so assessment and management should be family-centered rather than child-only. Key References McCavert M-E, Perra O, McConnell K, Kerr C. Sleep disturbances in children with cerebral palsy, their siblings, and parents: A qualitative descriptive study. *Developmental Medicine & Child Neurology.* First published 25 June 2026. 
Show More